×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABEO – abeona therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABEO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
01:20 pm
abeo
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB [Seeking Alpha]
Low
Report
Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB [Seeking Alpha]
3/19
08:22 am
abeo
Abeona Therapeutics (ABEO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Abeona Therapeutics (ABEO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
3/18
06:44 pm
abeo
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point [Seeking Alpha]
Low
Report
Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point [Seeking Alpha]
3/17
06:06 pm
abeo
Abeona Therapeutics (ABEO) was given a new $17.00 price target by Stifel Nicolaus.
Medium
Report
Abeona Therapeutics (ABEO) was given a new $17.00 price target by Stifel Nicolaus.
3/17
03:26 pm
abeo
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... [Yahoo! Finance]
Low
Report
Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... [Yahoo! Finance]
3/17
10:01 am
abeo
Abeona (ABEO) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Abeona (ABEO) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/17
08:13 am
abeo
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates [Yahoo! Finance]
Low
Report
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates [Yahoo! Finance]
3/17
07:35 am
abeo
Abeona Therapeutics GAAP EPS of $1.01 misses by $0.17, revenue of $5.82M beats by $0.6M [Seeking Alpha]
Medium
Report
Abeona Therapeutics GAAP EPS of $1.01 misses by $0.17, revenue of $5.82M beats by $0.6M [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/20
04:32 pm
abeo
Form 8-K ABEONA THERAPEUTICS INC. For: Mar 16
Low
Report
Form 8-K ABEONA THERAPEUTICS INC. For: Mar 16
3/17
07:36 am
abeo
Form 10-K ABEONA THERAPEUTICS INC. For: Dec 31
Medium
Report
Form 10-K ABEONA THERAPEUTICS INC. For: Dec 31
3/17
07:30 am
abeo
Form 8-K ABEONA THERAPEUTICS INC. For: Mar 17
Low
Report
Form 8-K ABEONA THERAPEUTICS INC. For: Mar 17
3/16
04:32 pm
abeo
Form 144 ABEONA THERAPEUTICS INC. Filed by: Vazzano Joseph Walter
Medium
Report
Form 144 ABEONA THERAPEUTICS INC. Filed by: Vazzano Joseph Walter
3/16
04:29 pm
abeo
Form 4 ABEONA THERAPEUTICS INC. For: Mar 16 Filed by: Vazzano Joseph Walter
Medium
Report
Form 4 ABEONA THERAPEUTICS INC. For: Mar 16 Filed by: Vazzano Joseph Walter
3/9
07:31 am
abeo
Form 8-K ABEONA THERAPEUTICS INC. For: Mar 09
Medium
Report
Form 8-K ABEONA THERAPEUTICS INC. For: Mar 09
2/12
09:08 am
abeo
Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
Low
Report
Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
2/9
04:02 pm
abeo
Form 144 ABEONA THERAPEUTICS INC. Filed by: Silverstein Christine Berni
Low
Report
Form 144 ABEONA THERAPEUTICS INC. Filed by: Silverstein Christine Berni
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/3
Abeona Therapeutics Announces Strategic Review
83.8%
3/16 Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates 40.7%
12/10 Abeona Therapeutics Inc (NASDAQ: ABEO) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $4.00 price target on the stock. 28.6%
10/15 Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa 21.0%
12/10 Form 8-K ABEONA THERAPEUTICS INC. For: Dec 09 20.7%
12/20 Form 25-NSE ABEONA THERAPEUTICS INC. Filed by: The Nasdaq Stock Market LLC 14.2%
2/10 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $6.00 price target on the stock. 11.4%
8/13 Abeona Therapeutics Inc (NASDAQ: ABEO) had its price target lowered by analysts at Royal Bank of Canada to $16.00. They now have a "positive" rating on the stock. 10.3%
2/11 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Leerink Swann. They set a "buy" rating and a $6.00 price target on the stock. 9.7%
1/21 Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa 9.4%
3/16 Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates 40.7%
12/10 Abeona Therapeutics Inc (NASDAQ: ABEO) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $4.00 price target on the stock. 28.6%
10/15 Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa 21.0%
12/10 Form 8-K ABEONA THERAPEUTICS INC. For: Dec 09 20.7%
12/20 Form 25-NSE ABEONA THERAPEUTICS INC. Filed by: The Nasdaq Stock Market LLC 14.2%
2/10 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $6.00 price target on the stock. 11.4%
8/13 Abeona Therapeutics Inc (NASDAQ: ABEO) had its price target lowered by analysts at Royal Bank of Canada to $16.00. They now have a "positive" rating on the stock. 10.3%
2/11 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Leerink Swann. They set a "buy" rating and a $6.00 price target on the stock. 9.7%
1/21 Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa 9.4%
TOP News Decliners
12/19
Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
-37.7%
7/25 Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA -20.0%
6/18 Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease -16.5%
3/17 Form SEC STAFF LETTER ABEONA THERAPEUTICS INC. -15.4%
9/23 Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa -11.9%
8/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. -11.1%
12/9 Abeo on go with late-stage study of RDEB gene therapy; shares up 3% [Seeking Alpha] -10.4%
10/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.1%
1/13 Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa -9.2%
12/4 Edited Transcript of ABEO earnings conference call or presentation 13-Nov-19 3:00pm GMT [Yahoo! Finance News] -8.6%
7/25 Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA -20.0%
6/18 Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease -16.5%
3/17 Form SEC STAFF LETTER ABEONA THERAPEUTICS INC. -15.4%
9/23 Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa -11.9%
8/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. -11.1%
12/9 Abeo on go with late-stage study of RDEB gene therapy; shares up 3% [Seeking Alpha] -10.4%
10/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.1%
1/13 Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa -9.2%
12/4 Edited Transcript of ABEO earnings conference call or presentation 13-Nov-19 3:00pm GMT [Yahoo! Finance News] -8.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: